Loss of fertility is one of the most important concerns facing Turner Syndrome (TS) patients as they transition into adult healthcare. Due to the limited and rapidly decreasing ovarian reserve many TS patients require fertility preservation (FP) techniques to preserve their reproductive potential until they are ready to pursue procreation. One has to also remember about the additional risks connected with pregnancy in TS patients. In order to determine the optimal time for introducing FP techniques and decrease the chance of an unnecessary intervention, markers and procedures assessing ovarian reserve have been developed. The exposure to potential cardiovascular complications should be determined before FP to avoid unnecessary procedures in patients with potential contraindications to pregnancy. The aim of the present review is to answer the following three questions important for successful preservation of fertility and safe pregnancy in TS. Which markers of ovarian reserve should be used as selection criteria for FP? Which methods of FP are the safest and most effective? If are there any cardiovascular contraindications to fertility preservation? For each of those questions separate literature searches have been conducted. A total of 86 articles have been included in this review, 34 for the first question, 35 for the second and 17 for the third. Ovarian reserve markers and cardiovascular contraindications to pregnancy should be established before FP, hoverer there are no unambiguous indicators which patients should be disqualified from the FP and more evidence is needed in this subject.

transition. In adolescents, however, puberty blocking agents [i.e. gonadotropin-releasing hormone agonist (GnRHa)] are the first-line treatment for younger persons entering puberty (Tanner stage ≥ G2/B2). GnRH agonists are also mentioned by some guidelines [3] to be used as routine gonadal axis suppression for all hormonally transitioning individuals. Many other agents have been mentioned as useful in GCHT depending on a person's transitional goals, although not unambiguously, and some with much controversy. These include, but are not limited to, cyproterone acetate and other progestins (e.g. medroxyprogesterone, lynestrenol), spironolactone, finasteride, or minoxidil. The SOC [1] and Endocrine Society CPG [2] specify